GO29781

An open-label, multicenter, phase I/IB trial evaluating the safety and pharmacokinetics of escalating doses of BTCT4465A as a single agent and combined with atezolizumab in patients with relapsed or refractory b-cell non-hodgkin’s lymphoma and chronic lymphocytic leukemia
Menu